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Abstract
Purpose
Radiofrequency thermal ablation (RFA) of hepatic and renal tumors can be accompanied
by non-desired tumorigenesis in residual, untreated tumor. Here, we studied the use of
micelle-encapsulated siRNA to suppress IL-6-mediated local and systemic secondary
effects of RFA.
Methods
We compared standardized hepatic or renal RFA (laparotomy, 1 cm active tip at 70±2°C for
5 min) and sham procedures without and with administration of 150nmmicelle-like nanopar-
ticle (MNP) anti-IL6 siRNA (DOPE-PEI conjugates, single IP dose 15 min post-RFA, C57Bl
mouse:3.5 ug/100ml, Fisher 344 rat: 20ug/200ul), RFA/scrambled siRNA, and RFA/empty
MNPs. Outcome measures included: local periablational cellular infiltration (α-SMA+ stel-
late cells), regional hepatocyte proliferation, serum/tissue IL-6 and VEGF levels at 6-72hr,
and distant tumor growth, tumor proliferation (Ki-67) and microvascular density (MVD,
CD34) in subcutaneous R3230 and MATBIII breast adenocarcinoma models at 7 days.
Results
For liver RFA, adjuvant MNP anti-IL6 siRNA reduced RFA-induced increases in tissue IL-6
levels, α-SMA+ stellate cell infiltration, and regional hepatocyte proliferation to baseline
(p<0.04, all comparisons). Moreover, adjuvant MNP anti-IL6- siRNA suppressed increased
distant tumor growth and Ki-67 observed in R3230 and MATBIII tumors post hepatic RFA
(p<0.01). Anti-IL6 siRNA also reduced RFA-induced elevation in VEGF and tumor MVD
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(p<0.01). Likewise, renal RFA-induced increases in serum IL-6 levels and distant R3230
tumor growth was suppressed with anti-IL6 siRNA (p<0.01).
Conclusions
Adjuvant nanoparticle-encapsulated siRNA against IL-6 can be used to modulate local and
regional effects of hepatic RFA to block potential unwanted pro-oncogenic effects of hepatic
or renal RFA on distant tumor.
Introduction
There has been much recent interest in using RNA interference (‘post-transcriptional gene
silencing’) and particularly small interfering RNAs (siRNA) in cancer therapies. This has
largely focused on either modulating cellular protein responses to improve efficacy of primary
pharmacologic/oncologic therapies [1,2], augmenting anti-tumor immunity through selective
knockdown of immune response suppressing proteins, or chemo-sensitization through silenc-
ing of growth factor receptor genes [3–6]. To overcome limitations in delivery with free siRNA
in in vivo systems, siRNAs have been commonly administered using nanoparticle carriers
(such as liposomes, micelles, or bound to particles) to maximize essentially passive tissue deliv-
ery (albeit in higher concentrations) to primary organs and target tumors [7–11]. Yet, even
aided by nanocarrier delivery, challenges to intra-tumoral and targeted drug delivery persist
[1,3]. Additionally, few studies have used adjuvant siRNA in conjunction with non-pharmaco-
logic paradigms, such as modulating tissue or physiologic responses after surgical, interven-
tional, or radiation treatments.
Image-guided thermal tissue ablation using radiofrequency, microwave, or laser energy to
create local high temperature (60–100°C) heating around a percutaneously placed applicator is
now in widespread clinical use to treat focal tumors of the liver, lung, kidney, and bone
(>100,000 cases/year worldwide) [12]. Successful complete tumor ablation also requires the
inclusion of a 5–10 mm rim of normal parenchyma as an ‘ablative margin’ to ensure complete
eradication the tumor [13]. In an attempt to ensure completeness of treatment, we have shown
that administration of even a single-dose of drug-loaded nanoparticle chemotherapy concur-
rently with RF ablation can lead to increases in local periablational drug delivery (up to
10-fold), with resultant increased tumor destruction, increased animal endpoint survival, and
greater amounts of tumor destruction in patients with hepatic tumors [14–16]. Recently we
have further successfully leveraged this improved focal delivery to target specific RFA-induced
tissue responses (such as increased DNA intercalation or suppressing HSP production) [16,17].
A number of studies have demonstrated that sub-lethal lower tissue heating (40–47°C)
around the ablation zone incites multiple secondary tissue reactions [18], including increased
inflammatory cytokine (such as IL-6 and IL-10) [19] and growth factor (such as HGF, HIF-1α,
and VEGF) [20–22] production; infiltration of scavenger and immunogenic cells into the peria-
blational tissue [23]; and hyperthermia-induced increases in vascular permeability and endo-
thelial leakiness [24]. In particular, recent studies have demonstrated that increased serum
Interleukin-6 production after thermal ablation of normal liver (simulating the clinical end-
point of ablating the entire liver tumor and its ‘ablative margin’ of normal surrounding liver) is
a key driver of periablational infiltration of inflammatory and immunogenic cells such as mac-
rophages and α-smooth muscle actin (SMA) positive hepatic stellate cells [23,25]. These, in
turn, can produce additional activation of downstream pro-growth pathways such as cytokines
siRNA-Loaded Nanoparticles Enhance Tumor Ablation
PLOS ONE | DOI:10.1371/journal.pone.0128910 July 8, 2015 2 / 18
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
in the HGF/c-Met pathway, and increased hepatocyte proliferation in untreated liver—pro-
cesses which are markedly reduced in IL-6 knockout mice [25]. Given that successful complete
tumor ablation also requires the inclusion of a 5–10 mm rim of normal parenchyma as an
‘ablative margin’ to ensure complete eradication the tumor[13], studying these secondary sys-
temic effects of RF ablation in normal organ tissue is imperative. The need for further study is
supported by recent experimental studies demonstrating, ‘off-target’ stimulation of distant
tumor growth after thermal ablation of liver and kidney tissue, and clinical studies that suggest
a higher incidence of new HCC after hepatic RF ablation (approaching 80% at 5 years) com-
pared to comparative un-treated cirrhotic patients (22–50%)[26–29]. Here, we build on our
earlier experience using nanoparticle-mediated drug delivery preferentially targeted to the peri-
ablational rim to study whether polymeric micelle-like nanoparticles (MNPs) loaded with anti-
IL6 siRNA can be used to suppress thermal ablation-induced IL-6 production, IL-6-mediated
periablational cell infiltration, hepatocyte proliferation in untreated liver, and IL-6-mediated
downstream RF ablation-induced stimulation of distant tumor growth.
Materials and Methods
Ethics statement
All animal studies were performed with the approval of the Beth Israel Deaconess Medical
Center Institutional Animal Care and Use Committee and Hadassah Hebrew University Medi-
cal School Institutional Animal Care Ethics Committee.
Animal models
For all experiments and procedures, anesthesia was induced with IP injection of a mixture of
ketamine (50 mg/kg, Ketaject; Phoenix Pharmaceutical, St. Joseph, MO) and xylazine (5 mg/
kg, Bayer, Shawnee Mission, KS). Animals were sacrificed with an overdose of carbon dioxide
using SMARTBOX CO2 Chamber System (EZ systems, Palmer, PA) followed by cardiac
puncture.
Experiments were performed in normal C57Bl mice (40±10g), or two breast adenocarci-
noma cell lines (R3230 or MATBIII) implanted subcutaneously in female Fisher 344 rats (150
±20g; 14–16 weeks old, Charles River, Wilmington, MA) [30]. The R3230 breast adenocarci-
noma tumor line is a well-characterized line that we have been using for over 10 years [30].
The MATBIII tumor line was obtained from American Type Culture Collection (ATCC,
Manassas, VA). Tumor implantation, evaluation, and preparation techniques were performed
as previously described [30]. Briefly, one tumor was implanted into each animal by slowly
injecting 0.3–0.4 mL of tumor suspension into the mammary fat pad of each animal via an
18-gauge needle. Tumors were measured every 1-2d until they reached 6–7 mm at which point
they were included in studies.
Application of RF ablation
Conventional monopolar RFA was applied by using a 500-kHz RFA generator (model 3E;
Radionics, Burlington, MA), as has been previously described [30]. Briefly, the target organ
was exposed via laparotomy using a subcostal (liver) or lateral (kidney) incision under sterile
conditions while the animal was anesthetized. The 1-cm tip of a 21-gauge electrically insulated
electrode (SMK electrode; Cosman Medical Inc, Burlington, MA) was placed in the liver or kid-
ney. For animals treated with thermal ablation, RF energy was applied for 5 min with generator
output titrated to maintain a designated tip temperature (70±2°C). This standardized method
of RF application has been demonstrated previously to provide reproducible coagulation
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volumes with use of this conventional RFA system [30,31]. To complete the RF circuit, the ani-
mal was placed on a standardized metallic grounding pad (Radionics). For animals treated
with either sham or an agent alone, the electrode was placed, but no energy was administered.
Nanoparticle siRNA formulation
All materials were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Branched polyethylenimine (PEI) with a molecular weight of 1.8 kDa was purchased from Poly-
sciences, Inc (Warrington, PA). 1,2-disrearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] (PEG-PE 2kDa) and 1,2-dioleoyl-sn-glycero-3-phosphoethanola-
mine-N-(glutaryl) (Glutaryl-PE) were purchased from Avanti Polar Lipids (Alabaster, AL).
Nuclease-free water was purchased from Qiagen (Germantown, MD). All siRNA duplexes are
from Dharmacon (Lafayette, CO). The synthesized sequences of siRNA targeting IL-6 were:
5’-AGUCGGAGGCUUAAUUACAdTdT-3’(sense), 5’-CAGGAAAUUUGCCUAUUGAdTdT-3’
(sense) and 5’-UAAGGACCAAGACCAUCCAdTdT-3’(sense)[32,33]. A scramble siRNA was
used as negative control. The sequence of non-targeting control siRNA was 5’-AGUACUG
CUUACGAUACGGdTdT-3’ (sense) [34].
Micelle-like nanoparticles were selected as the delivery vehicle based upon prior work dem-
onstrating beneficial temporal delivery kinetics (6–12hr) and greater interstitial penetration in
tissues surrounding the ablation zone [35]. We constructed micelle-like nanoparticles (MNPs)
based on phospholipid modified-polyethylenimine conjugates (DOPE-PEI). The DOPE-PEI
conjugate and the DOPE-PEI/siRNA complexes were prepared as previously described [34].
We have previously demonstrated that DOPE-PEI conjugates based on low molecular weight
PEI self-assembled within micellar structures that condensed siRNA, showed high transfection
efficiency and had a better toxicity profile than PEI 25 kDa and Lipofectamine (commonly
used DNA/siRNA transfection reagents) [11]. We incorporated PEG-PE in the carriers to
achieve an improved performance in vivo. The hydrophobic interactions between the lipid
moieties in DOPE-PEI and those in PEG-PE resulted in their self-assembly into micelle-like
particles with a mean size of 150 nm and provide some steric stabilization of complexes by
forming a protective barrier and promoting increased stability in vivo. The DOPE-PEI/siRNA
complexes were prepared by mixing equal volumes of DOPE-PEI with siRNA-IL-6 (equimolar
pool of 3 sequences) or scramble siRNA to a final N/P ratio of 16. The siRNA solution was
transferred to the polymer solution, mixed by vigorous pipetting and incubated for 15 min.
The polymer/siRNA ratio was expressed as the nitrogen/phosphate (N/P) ratio, and calculated
assuming that 43 g/mol corresponds to each repeating unit of PEI containing one amine and
316 g/mol corresponds to each repeating unit of siRNA containing one phosphate. Then, a pre-
viously freeze-dried lipid film of PEG-PE was hydrated with the complexes and allowed to
stand at room temperature for 1h with intermittent shaking The PEG-PE2kDa:DOPE-PEI
weight ratio was 2:1 [36]. Empty formulations were prepared by the hydration of the film with
polymer solution only. Each mouse received a dose of 3.5 μg of siRNA in a final formulation
volume of 100 μL. Each rat received a dose of 20 μg of siRNA in a final formulation volume of
200 μL. Each dose was administered by intraperitoneal injection (IP) at selected time points as
specified above.
Tumor harvesting
Animals were sacrificed at specified times outlined above using carbon dioxide euthanasia. The
target tissue (primary site of ablation, untreated liver lobe, or distant tumor) was harvested,
and sectioned perpendicularly to the direction of electrode insertion [17,30]. Distant tumors
were also harvested and sectioned. All samples were fixed in 10% formalin overnight at 4°C,
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embedded in paraffin, and sectioned at a thickness of 5 μm. Tissues were stained with H&E for
gross pathology.
Quantification of IL-6 and VEGF levels
Serum and tissue levels of IL-6 (Mouse/M6000B and Rat /R6000B Quantikine kit, R&D Sys-
tems Inc., Minneapolis, MN) and VEGF (Rat/RRV00 Quantikine kit, R&D Systems) were
determined using an enzyme-linked immunosorbent assay (ELISA) kit according to manufac-
turer’s instructions. Briefly, flash-frozen liver tissue was homogenized in a cold lysis buffer
(Cell Signaling Technology Inc., Beverly, MA) consisting of a 0.1% proteinase inhibitor
(Sigma-Aldrich). The homogenates were then centrifuged at 14,000 rpm for 20 min at 4°C, and
the total protein concentration was determined using a bichinchoninic acid method (BCA)
(Sigma-Aldrich). Undiluted serum was used. IL6 and VEGF values were then normalized to
protein concentration. All samples and standards were measured in duplicate, and the average
value was recorded as pg per mL [37,38].
Immunohistochemical staining
Sections from ablated tissue and distant tumors were prepared and immunohistochemistry
staining was performed for the following markers: α-SMA (hepatic stellate cells in the periabla-
tional rim), CDC-47 (hepatocyte proliferation, untreated liver) (has been previously described
(Santa Cruz Biotechnology, Dallas, TX) [17,23]), Ki-67 (ab-16667 Abcam, Cambridge, MA)
(tumor cell proliferation in distant tumor), and CD34 (microvascular density in distant tumor)
(AF4117 R&D systems, Minneapolis, MN). Specimen slides were imaged and analyzed using a
Micromaster I microscope (Fisher Scientific, Pittsburgh, PA) and Micron Imaging Software
(Westover Scientific, Inc., Mill Greek, WA). Five random high power fields were analyzed for a
minimum of 3 specimens for each parameter and scored in a blinded fashion to remove
observer bias [16,17]. As an additional control to insure uniformity of staining, whenever direct
comparisons were made, IHC was repeated with all relevant comparison slides stained at the
same time.
Statistical Analysis
The SPSS 13.0 software package (SPSS Inc., Chicago, IL) was used for statistical analysis. All
data were provided as mean plus or minus SD. Selected (Day 0 and at the time of sacrifice)
mean tumor sizes, and immunohistochemical quantification were compared using analysis of
variance (ANOVA). Additional post-hoc analysis was performed with paired, two-tailed Stu-
dent’s T-test, if and only if, the analysis of variance achieved statistical significance. A P value
of less than 0.05 was considered significant. Tumor growth curves after treatment were ana-
lyzed using goodness-of-fit characterization. Mean post-treatment growth curve slopes plus or
minus SD were also calculated and compared using ANOVA and paired, two-tailed T-tests.
Results
Nanoparticle anti-IL6 siRNA blocks local periablational and regional
distant intrahepatic effects of thermal ablation
Initial hepatic RF ablation studies were performed in normal C57Bl mice using standardized
protocols to allow comparison to prior studies in normal and IL-6 knockout mice [25]. The fol-
lowing 6 treatment arms were compared (n = 5–6 animals/arm): hepatic RF thermal ablation
alone (laparotomy and RF application for 5 min, tip temperature titrated to 70±2°C), sham
procedure (laparotomy and needle placement without heating), RFA/MNP anti-IL6 siRNA
siRNA-Loaded Nanoparticles Enhance Tumor Ablation
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(single dose of 3.5 μg siRNA given IP, 15 min post-ablation), RFA/MNP scrambled siRNA,
MNP anti-IL6 siRNA alone, RFA/empty vehicle. Hepatic RF ablation increased local periabla-
tional tissue IL-6 levels compared to sham procedure at 12hr after treatment (1,463±108pg/ml
vs. 1061±45pg/ml, p = 0.004, Fig 1A). Adjuvant MNP anti-IL6 siRNA given with hepatic RFA
reduced local tissue IL-6 levels (1,139±159pg/ml; p = 0.04 vs. RFA alone, p = 0.46 vs. sham).
Hepatic RFA/MNP scrambled siRNA increased local tissue IL-6 levels (1,924±141pg/ml;
p<0.001 vs. sham, p = 0.01 vs. RFA alone, p =<0.001 vs. RFA/anti-IL6 siRNA). Tissue IL-6
levels after MNP anti-IL6 siRNA with sham treatment was 1,110±42pg/ml, and after RFA/
empty carrier was 1783±125pg/ml.
As reported previously [23], standardized RF thermal ablation of normal liver resulted in
infiltration of the periablational rim by α-SMA-positive activated myofibroblasts (also known
as hepatic stellate cells, a surrogate marker for the complex periablational cellular infiltration
that occurs after thermal ablation) at 4 days after treatment (60.1±26.3% positive cells/hpf
within the rim, Fig 1B–1E). Adjuvant MNP anti-IL6 siRNA significantly reduced α-SMA posi-
tive periablational cellular infiltration compared to other treatment arms (31.7±14.3% positive
cells/hpf vs. RF alone: 60.1±26.3%; RF/scrambled siRNA: 72.9±33.0%; p<0.001; Fig 1F). Both
the sham procedure alone or combined with MNP anti-IL6 siRNA alone did not result in any
increase in or other changes to periablational cellular infiltration.
Fig 1. Hepatic thermal ablation increases liver IL-6 levels at 12hr post-treatment and periablational α-
SMA+ activatedmyofibroblasts infiltration—which are suppressed with single dose adjuvant
nanoparticle anti-IL6 siRNA. (A) Liver ELISA quantification of IL-6 levels 12hr after treatment
(mean ± standard deviation). C57Bl mice were randomized to receive sham treatment, liver RF ablation, liver
RFA / IP MNP anti-IL6 siRNA, MNP anti-IL6 siRNA alone, RFA / MNP scrambled siRNA, or RFA / empty
carrier (n = 5–6 per group). Liver RFA increased local 12hr liver IL-6 levels (1,463±108 pg/ml) which was
suppressed with adjuvant IP MNP anti-IL6 siRNA (1,139±159 pg/ml, p = 0.04). Additionally, adjuvant MNP
anti-IL6 siRNA given 15 minutes after hepatic thermal ablation (D, E) in C57Bl mice suppressed
periablational infiltration of α-SMA positive myofibroblasts compared to hepatic thermal ablation alone (B) or
RFA combined with scrambled siRNA (C) (F, mean ± standard deviation, p<0.01).
doi:10.1371/journal.pone.0128910.g001
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Adjuvant MNP anti-IL6 siRNA also had organ-wide effects after hepatic thermal ablation.
As shown by Rozenblum et al [25], thermal ablation of one lobe of the liver increased hepato-
cyte proliferation in the distant, untreated liver lobe, as measured by CDC47 staining (a marker
of cells entering the G1 phase of cell replication) (42.016.2% positive cells/hpf, Fig 2). MNP
anti-IL6 siRNA reduced the amount of hepatocyte proliferation compared to liver thermal
ablation alone (23.0±10.7%/hpf vs. 42.016.2%/hpf, p<0.001). No difference was observed in
hepatocyte proliferation in a distant, untreated liver lobe for RFA/MNP scrambled siRNA
(28.1±16.7%/hpf) compared to RF ablation alone (p = 0.12) or RFA/MNP anti-IL6 siRNA
(p = 0.15) [Fig 2A–2D].
Nanoparticle anti-IL6 siRNA suppresses thermal ablation-induced
stimulation of distant R3230 tumor growth and serum IL-6 levels after RF
ablation of normal liver parenchyma
To determine the impact on distant tumor growth to simulate the common condition of dis-
tant metastases, we used a subcutaneous breast tumor model (R3230) in which hepatic RF abla-
tion has been associated with distant tumor growth [26]. Here, the following treatment arms
were compared (n = 6–7 animals/arm): hepatic RF thermal ablation alone, sham procedure,
RFA/MNP anti-IL6 siRNA (20 mcg of siRNA, IP delivery), RFA/MNP scrambled siRNA,
MNP anti-IL6 siRNA alone, RFA/empty vehicle. The effect of these six treatment arms on dis-
tant subcutaneous tumor growth was assessed. All tumors grew at the same rate over 5d prior
to randomization to various treatment arms. Thermal ablation of normal liver increased dis-
tant R3230 tumor growth for 7d after treatment compared to sham/control treatment
(p<0.001; Fig 3A, Table 1). Adjuvant MNP anti-IL6 siRNA suppressed the thermal ablation-
induced effects on distant R3230 tumor growth such that the mean tumor size at 7d with
Fig 2. Adjuvant nanoparticle anti-IL6 siRNA suppresses thermal ablation-induced hepatocyte
proliferation in the untreated, distant hepatic lobe. Adjuvant MNP anti-IL6 siRNA given 15 minutes after
hepatic thermal ablation (C) in C57Bl mice (n = 5–6 animals/arm) suppressed hepatocyte proliferation in the
distant, untreated liver lobe (with CDC47 staining, mean ± standard deviation) compared to hepatic thermal
ablation alone (A, D, p<0.01). Hepatic thermal ablation combined with MNP scrambled siRNA was not
significantly different from either thermal ablation alone or ablation combined with MNP anti-IL6 siRNA (B, D).
doi:10.1371/journal.pone.0128910.g002
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combination therapy was lower than either the sham (non-ablation) and hepatic RFA alone
groups (p = 0.02 vs. sham, p<0.001 vs. hepatic RFA alone; Fig 3A, Table 1). Hepatic RF abla-
tion combined with MNP scrambled siRNA resulted in the largest distant tumor diameter at
7d compared to all other treatment arms (19.3±1.7mm, p<0.03 for all comparisons).
Tumor proliferative index (Ki-67) in the distant R3230 subcutaneous tumor was measured
for all treatment arms [Fig 3B, Table 1]. Hepatic thermal ablation increased distant tumor pro-
liferation at 7d compared to the sham procedure (p = 0.001). Combination adjuvant MNP
anti-IL6 siRNA and hepatic thermal ablation significantly reduced distant tumor proliferation
(p = 0.045 vs. sham, p<0.001 vs. hepatic RFA alone). Thermal ablation combined with either
empty carrier or MNP scrambled siRNA resulted in increased distant tumor prolilferation
(p<0.04 compared to sham treatment). There was no difference between sham treatment and
MNP anti-IL6 siRNA alone arms (p = 0.59).
Fig 3. Hepatic thermal ablation-induced distant subcutaneous R3230 tumor growth is suppressed
with adjuvant nanoparticle anti-IL6 siRNA. (A) Subcutaneous R3230 tumors implanted in Fisher 344 rats
with similar growth rates were randomized at Day 0 to one of six different treatment arms (n = 6–7 animals/
arm). Hepatic thermal ablation alone or combined with either empty carrier or MNP scrambled siRNA resulted
in significantly greater tumor growth and change in diameter (5d before to 7d after treatment) compared to
sham treatment (p<0.01 for all comparisons, mean ± standard deviation for all numbers presented). Adjuvant
MNP anti-IL6 siRNA combined with thermal ablation resulted in distant tumor growth rate and end diameter
that was the lowest of all treatment arms (p<0.01 for all comparisons). (B) Adjuvant MNP anti-IL6 siRNA
combined with hepatic thermal ablation also reduced distant tumor proliferation (Ki-67) to sham levels
compared to hepatic thermal ablation alone or combined with empty carrier or MNP scrambled siRNA
(p<0.01 for relevant comparisons). (C) Hepatic thermal ablation alone or with MNP scrambled siRNA
increased serum IL-6 levels at 6hr compared to the sham procedure (n = 3–4 animals/arm, p<0.02). This
effect was suppressed with adjuvant MNP anti-IL6 siRNA (p = 0.03 vs. RF liver alone). (D) Comparison of the
effect of siRNA administration timing showed that adjuvant MNP anti-IL6 siRNA administered at Day 0
resulted in the lowest post-treatment tumor growth rate and endpoint diameter (n = 3–4 animals/arm, p<0.05
for all comparisons). Adjuvant MNP anti-IL6 siRNA administered 3d post-ablation reduced the endpoint
diameter compared to hepatic ablation alone, but was still significantly greater that either sham or combined-
Day 0 treatment (p<0.05 for all comparisons).
doi:10.1371/journal.pone.0128910.g003
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Next, serum IL-6 levels were quantified by ELISA at 6hr after treatment for each of the six
arms (n = 3–4 animals/arm) to determine the effect of adjuvant MNP anti-IL6 siRNA on abla-
tion-induced systemic IL-6 levels. This time point was selected as serum IL-6 levels peaked at
6hr in this model post-hepatic RFA. Serum IL-6 levels were increased after thermal hepatic
ablation (266±9pg/ml) compared to sham treatment (199±18pg/ml, p = 0.005) [Fig 3C]. The
addition of MNP anti-IL6 siRNA reduced serum IL6 levels at 6hr (229±16pg/ml) compared to
RFA alone (p = 0.03) or RFA/MNP scrambled siRNA (298±18pg/ml, p = 0.02). RFA/empty
carrier also increased serum IL6 levels at 6hrs similar to RFA alone (298±18pg/ml, p = 0.57).
Finally, timing of siRNA administration was compared, and MNP anti-IL6 siRNA adminis-
tered immediately after hepatic RFA (Day 0) resulted in complete suppression of RFA-induced
tumor growth compared to administration at a later time point (3d) after hepatic RFA (Day 0
vs. Day 3, p<0.02) [Fig 3D, Table 1]. Similarly, for the hepatic RFA / nano anti-IL6 siRNA at
Day 0, the tumor proliferative index at 7d was significantly lower compared to Day 3 adminis-
tration (p = 0.001).
Nanoparticle anti-IL6 siRNA suppresses hepatic ablation-induced
distant tumor growth through reduction in VEGF-mediated tumor
angiogenesis
Periablational liver tissue levels of VEGF were increased after thermal ablation, peaking at
72hr. Here, tissue VEGF levels in the periablational rim were compared using ELISA at 72hr
after treatment for the following arms: hepatic RF thermal ablation alone, sham procedure,
Table 1. Evaluation of distant tumor after thermal ablation without and with adjuvant MNP siRNA.
Treatment arms End tumor
diameter (mm)
Change in diameter
after treatment(mm)
Pre Growth
Curve Slope
Post Growth
Curve Slope
Tumor Ki-67 (%
cell positivity/hpf)
MVD / CD34
(vessel # per hpf)
LIVER thermal ablation without and with anti-IL6 siRNA on distant R3230 tumor growth (7d)
Sham treatment 13.8 ± 0.8 5.7 ± 1.1 0.64 ± 0.12 0.37 ± 0.16 24.7 ± 3.6 25.1 ± 8.1
RFA liver alone 17.0 ± 2.0 9.1 ± 1.7 0.62 ± 0.08 0.89 ± 0.24 70.1 ± 8.6 50.9 ± 15.9
RFA liver + anti-IL6
siRNA (given at Day 0)
12.6 ± 1.5 4.2 ± 1.0 0.75 ± 0.50 0.20 ± 0.01 18.3 ± 1.4 22.9 ± 3.2
anti-IL6 siRNA alone 14.7 ± 1.0 6.7 ± 1.0 0.59 ± 0.21 0.59 ± 0.18 27.4 ± 7.2 29.1 ± 1.0
RFA liver + scramb
siRNA
19.3 ± 1.7 12.0 ± 2.1 0.65 ± 0.11 1.25 ± 0.30 37.8 ± 6.3 56.3 ± 3.1
RFA liver + empty
carrier
17.1 ± 0.4 9.9 ± 0.5 0.65 ± 0.12 0.99 ± 0.09 46.1 ± 6.0 49.3 ± 7.8
RFA liver + anti-IL6
siRNA (given at Day 3)
15.5 ± 1.0 7.0 ± 0.9 0.85 ± 0.21 0.55 ± 0.49 28.2 ± 1.5 30.6 ± 2.8
KIDNEY thermal ablation without and with anti-IL6 siRNA on distant R3230 tumor growth (7d)
Sham treatment 14.5 ± 1.2 6.4 ± 0.7 0.65 ± 0.11 0.45 ± 0.08 15.5 ± 5.6 16.9 ± 2.3
RFA kidney alone 19.6 ± 1.8 11.2 ± 1.5 0.61 ± 0.07 1.18 ± 0.26 45.1 ± 4.3 33.1 ± 4.4
RFA kidney + anti-IL6
siRNA
13.9 ± 1.2 5.7 ± 1.2 0.64 ± 0.22 0.35 ± 0.16 19.4 ± 2.0 19.6 ± 0.5
Anti-IL6 siRNA alone 15.7 ± 0.3 7.0 ± 0.9 0.75 ± 0.15 0.50 ± 0.16 28.4 ± 3.6 26.4 ± 0.9
LIVER thermal ablation without and with anti-IL6 siRNA in a SECOND TUMOR (MATBIII) (3.5d)
Sham treatment 21.9 ± 1.2 11.4 ± 1.5 1.83 ± 0.21 0.39 ± 0.20 57.5 ± 7.7 32.8 ±7.9
RFA liver alone 24.4 ± 2.5 14.7 ± 2.0 1.86 ± 0.44 0.77 ± 0.20 75.8 ± 1.7 49.9 ± 7.3
RFA liver + anti-IL6
siRNA
20.6 ± 1.7 11.5 ± 1.0 1.80 ± 0.14 0.27 ± 0.22 44.8 ± 6.9 15.9 ± 0.9
All numbers provided as mean ± standard deviation.
doi:10.1371/journal.pone.0128910.t001
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RFA/MNP anti-IL6 siRNA (20g of siRNA, IP delivery), RFA/MNP scrambled siRNA, MNP
anti-IL6 siRNA alone, RFA/empty vehicle (n = 3–4 animals/arm). Hepatic ablation increased
periablational tissue VEGF levels compared to sham treatment at 72hr (2359±233pg/ml vs.
1429±83pg/ml, p = 0.002) [Fig 4A]. Adjuvant MNP anti-IL6 siRNA reduced liver VEGF levels
after thermal ablation (1799±71pg/ml, p = 0.02 vs. ablation). Hepatic ablation combined with
adjuvant scrambled siRNA led to similar liver VEGF levels compared to RFA alone (2229
±42pg/ml; vs. RFA alone: p = 0.51; vs. sham: p = 0.001). No difference was observed for thermal
ablation combined with the empty carrier compared to other treatment arms (1804±370pg/ml;
vs. RFA alone: p = 0.09; vs. sham: p = 0.16). MNP anti-IL6 siRNA alone had greater liver tissue
VEGF levels compared to sham (2234±195pg/ml, p = 0.002).
Microvascular density (using CD34 staining) was then compared in distant subcutaneous
tumors for each of the six treatment arms at 7d post-treatment [Fig 4B–4E, Table 1]. Hepatic
thermal ablation increased distant tumor microvascular density at 7d compared to the sham
procedure (p = 0.003). Combination adjuvant MNP anti-IL6 siRNA and hepatic thermal
ablation significantly reduced distant tumor microvascular density (p = 0.01 vs. hepatic RFA
alone). Thermal ablation combined with either empty carrier or scrambled siRNA resulted
in increased distant tumor microvascular density (p<0.003 compared to sham treatment).
There was no difference between sham treatment and MNP anti-IL6 siRNA alone arms
(p = 0.46). These findings suggest that blocking of hepatic ablation-induced distant tumor
growth by adjuvant anti-IL6 siRNA is mediated by suppression of downstream VEGF pro-
duction and distant tumor angiogenesis.
Nanoparticle anti-IL6 siRNA suppresses distant tumor growth after RF
ablation in a second primary organ site (normal kidney)
For tumor growth studies, kidney RF thermal ablation alone, sham procedure, RFA/MNP
anti-IL6 siRNA (20g of siRNA, IP delivery), and MNP anti-IL6 siRNA alone were compared
Fig 4. Adjuvant nanoparticle anti-IL6 siRNA suppresses hepatic ablation-induced distant
subcutaneous R3230 tumor growth via reduction in VEGF-mediated angiogenesis. (A) Tissue levels of
VEGF (Y-axis2, dark gray columns) in the periablational tissue surrounding the ablation zone were quantified
at 72hr after different treatments (mean ± standard deviation, n = 3–4 animals/arm). Hepatic thermal ablation
increased periablational VEGF levels, which were then suppressed with adjuvant MNP anti-IL6 siRNA
(p<0.05 for all comparisons). (B-E) Similarly, hepatic thermal ablation led to increased microvascular density/
angiogenesis (immunohistochemistry for CD34, A: Y-axis1, light gray columns) in distant subcutaneous
R3230 tumor that was also suppressed with adjuvant anti-IL6 siRNA (n = 6–7 animals/arm).
doi:10.1371/journal.pone.0128910.g004
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(n = 6–7 animals/arm). Similarly, RF ablation of normal kidney increased distant R3230
tumor growth compared to sham treatment that was also suppressed with single-dose adju-
vant MNP anti-IL6 siRNA (given at Day 0) [Fig 5A, Table 1]. Tumor proliferative index and
microvascular density for combination nanoparticle anti-IL6 and sham arms were equivalent
to each other and lower compared to the group treated with RF ablation of normal kidney
alone [Fig 5B, Table 1].
Next, serum IL6 levels were studied in the following treatment arms: kidney RF thermal
ablation alone, sham procedure, RFA/MNP anti-IL6 siRNA (20g of siRNA, IP delivery), RFA/
MNP scrambled siRNA, MNP anti-IL6 siRNA alone, RFA/empty vehicle (n = 3–4 animals/
arm). Serum IL-6 levels (quantified by ELISA 6hr after thermal ablation) were increased after
kidney thermal ablation (342±32pg/ml) compared to sham treatment (243±23pg/ml,
p = 0.005) [Fig 5C]. The addition of MNP anti-IL6 siRNA reduced serum IL6 levels at 6hr (219
±25pg/ml) compared to RFA alone (p = 0.03) or RFA/MNP scrambled siRNA (283±12pg/ml,
p = 0.02). RFA/empty carrier also increased serum IL6 levels at 6hr similar to RFA alone (278
±38pg/ml, p = 0.57).
Fig 5. Thermal ablation of a second primary organ (kidney) leads to increased distant subcutaneous
R3230 tumor growth that is suppressed with adjuvant nanoparticle anti-IL6 siRNA. (A) Subcutaneous
R3230 tumors implanted in Fisher 344 rats with similar growth rates were randomized at Day 0 to one of four
different treatment arms (n = 6–7 animals/arm). Thermal ablation of normal kidney alone resulted in
significantly greater tumor growth and change in diameter (5d before to 7d after treatment) compared to sham
treatment or MNP anti-IL6 siRNA alone (p<0.01 for all comparisons, mean ± standard deviation for all data).
MNP anti-IL6 siRNA combined with thermal ablation reduced distant tumor growth rate and endpoint
diameter to baseline sham levels. (B) Adjuvant MNP anti-IL6 siRNA combined with kidney thermal ablation
also reduced distant tumor proliferation (Ki-67) and microvascular density (CD34) to baseline levels
compared to kidney thermal ablation alone (p<0.01 for relevant comparisons). (C) Adjuvant MNP anti-IL6
siRNA suppressed kidney thermal ablation-induced elevations in serum IL-6 levels at 6hr post-treatment
(n = 3–4 animals/arm, p = 0.006).
doi:10.1371/journal.pone.0128910.g005
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Nanoparticle anti-IL6 siRNA suppresses distant tumor growth in a
second tumor model (MATBIII) after hepatic thermal ablation
Next, the effect of MNP anti-IL6 siRNA on hepatic thermal ablation was assessed in a second
subcutaneous tumor model (MATBIII rat breast adenocarcinoma line) at 3.5d post-treatment
(due to the relatively faster innate tumor growth rate, all tumors reached the mandated size for
sacrifice after 3.5d) [Table 1]. Hepatic thermal ablation without and with adjuvant IP MNP
anti-IL6 siRNA was compared to sham treatment (n = 6–7 animals/arm). All tumors grew at
the same rate over 2.5d prior to randomization to treatment. Hepatic thermal ablation again
resulted in significantly larger distant subcutaneous MATBIII tumors at 3.5d compared to the
sham procedure (p = 0.001, Fig 6). Adjuvant MNP anti-IL6 siRNA post-ablation reduced the
tumor growth rate such that endpoint diameter was significantly smaller than hepatic ablation
alone, and equal to the sham arm (vs. RFA alone p = 0.009, vs. sham p = 0.94, Table 1). RFA
alone also resulted in significantly greater cellular proliferation and microvascular density in
the distant MATBIII tumor compared to RFA with MNP anti-IL6 siRNA or sham treatment
(p<0.05 for all comparisons, Table 1).
Discussion
Several studies have reported that incomplete thermal tumor ablation of intrahepatic or renal
tumors can have either stimulatory or suppressive effects on tumor cell growth in the partially
Fig 6. Hepatic thermal ablation-induced distant tumor growth is suppressed with adjuvant
nanoparticle anti-IL6 siRNA in a second breast adenocarcinoma tumor model (MATBIII).
Subcutaneous MATBIII tumors implanted in Fisher 344 rats with similar growth rates were randomized at Day
0 to one of three different treatment arms (sham treatment and hepatic RF ablation without and with adjuvant
IP MNP anti-IL6 siRNA; n = 6–7 animals/arm). Given the rapid growth rate of this line, tumors were measured
twice daily 2.5d pre- to 3.5d post-treatment (mean ± standard deviation). Hepatic thermal ablation resulted in
a significantly larger endpoint tumor diameter compared to the sham group (p<0.05). Adjuvant MNP anti-IL6
siRNA suppressed the effects of hepatic thermal ablation, such that endpoint tumor diameter was equivalent
to the sham group.
doi:10.1371/journal.pone.0128910.g006
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injured residual cells present in periablational tissue or in intrahepatic/intra-organ tumor foci
separate from the ablation site [21,22,39,40]. For example, Nijkamp et al. reported increases in
periablative tumor outgrowth after incomplete ablation of murine intrahepatic colorectal
metastases [21]. Regardless, potential RF ablation-induced stimulation of distant extrahepatic
tumor growth remains poorly characterized. Here, we confirm recent reports that thermal
ablation of normal organ parenchyma (such as liver or kidney) can stimulate distant tumor
growth in at least two different tumor models [27], and further demonstrate that this in part
due to ablation-induced increases in IL-6. Ultimately, this is potentially very clinically relevant,
as the standard clinical endpoint in widespread practice is to ablate the entire tumor and up to
a 5–10 mm circumferential margin of normal parenchymal tissue around the ablation zone
[41]. Additionally, thermal ablation is increasingly applied as the primary treatment of oligo-
metastatic disease, as part of multi-modality treatments where other existing tumors are being
treated differently, or to target active metastatic foci in combination with systemic chemother-
apy—all circumstances where small viable tumor cells are likely present separate from the abla-
tion zone [42–44]. Therefore, for virtually all clinical cases of successful thermal tumor
ablation, the potential for stimulation of tumor foci elsewhere in the body exists.
Our study further demonstrates that adjuvant nanoparticle siRNA can be successfully used
to target IL-6 mediated locoregional and systemic effects of thermal ablation. Specifically, adju-
vant siRNA can be used to suppress thermal ablation-induced increases in local and serum IL-
6 cytokine levels, alter cellular infiltration patterns surrounding local thermal ablation, affect
liver physiology/homeostasis by reducing ablation-induced hepatocyte proliferation in
untreated liver, and achieve systemic suppression of un-intended ‘off-target’ distant pro-onco-
genic effects of thermal ablation. Furthermore, we demonstrate that these RF-induced effects
occur in various settings (here, in two tumor models, two organs, and two species), are IL6-me-
diated in these scenarios, and most importantly that they can be reproducibly modulated and
attenuated with nano-delivered siRNA.
Thermal ablation incites several additional local tissue reactions, including increased oxida-
tive and nitrative stress-mediated apoptosis and production of local tissue factors such as heat
shock proteins, hepatocyte growth factor, and pro-angiogenic VEGF, HIF-1α, and PDGF
[14,18,21,22]. Here, we also show that suppressing IL-6 with adjuvant siRNA blocks down-
stream production of VEGF and distant tumor angiogenesis, underscoring the potential utility
of using adjuvant siRNA when the target is sufficiently upstream in the pathway. Additionally,
while several of these pathways are linked to IL-6, those that are not could also potentially be
targeted using other siRNAs to suppress production of alternative key proteins/mediators.
Our successful ‘proof-of-concept’ study demonstrates that nano-delivered siRNA can be
used to suppress the secondary local and systemic ‘off-target’ effects (such as IL6-mediated
inflammation) occurring after at least one clinically common procedure. Yet, there is also
broader potential clinical applicability of this approach, as thermal ablative techniques have
been incorporated into the treatment of a large number of diseases, including therapies such as
pulmonary vein ablation for cardiac arrhythmias, esophageal ablation of Barrett’s esophagus,
and in newer endovascular treatments for renovascular hypertension, mitral regurgitation, vas-
cular stenosis, and venous reflux disease [45–48]. For several of these, secondary systemic
inflammatory reactions (mediated by cytokines such as IL-6, C-reactive protein, and tumor
necrosis factor) have been linked to treatment failure [49,50], and have been the basis for the
incorporation of adjuvant peri-procedural anti-inflammatory drug therapies [51,52].
One of the main limitations of transitioning siRNA to therapeutic applications has been due
to challenges in drug-delivery [53]. In particular, free siRNA has a very short blood circulating
half-life (on the order of minutes to an hour), making target-site accumulation a critical barrier
to siRNA efficacy [1,54]. Nanocarrier delivery has been one strategy studied to overcome
siRNA-Loaded Nanoparticles Enhance Tumor Ablation
PLOS ONE | DOI:10.1371/journal.pone.0128910 July 8, 2015 13 / 18
obstacles of targeted delivery and extracellular siRNA breakdown by facilitating direct internal-
ization through membrane fusion [55]. We have previously shown that nanocarriers preferen-
tially accumulate around in the rim of tissue immediately surrounding the ablation zone due to
heat-induced increases in vasodilation and endothelial leakiness [14,24,31]. Here, we show that
thermal tissue ablation and nanocarrier anti-IL6 siRNA are particularly complementary as we
take advantage of the fact that heating-induced vascular permeability occurs in the same geo-
graphic tissue region where infiltrating cells and increased IL-6 production is taking place,
resulting in sufficiently high concentrations of anti-IL6 siRNA to render it effective in altering
the cellular milieu and its composition. Given the predicTable and significant increases in
nanoparticle delivery that can be achieved around tissue ablation or with targeted low-level
hyperthermia, this combination strategy could potentially be used to facilitate siRNA delivery
for other diseases that do not specifically require tissue heating but may benefit from higher
levels of interstitial siRNA delivery. In addition to increased targeting specificity, additional
advantages of this combination paradigm concentrating siRNA near cells that are the intended
target (and conversely, minimizing exposure to non-target ‘normal’ cells), and increasing
silencing potency by achieving higher local delivery.
We acknowledge several limitations in this study. Although we have focused on the pro-
oncogenic effects of tumor ablation-induced inflammation, several studies have reported upon
the potential for ablation-induced anti-tumor immunity (either alone or in combination with
immunomodulation) with resultant tumor growth suppression [39,56–58]. While immuno-
genic effects of hepatic RF ablation are beyond the scope of this study, clearly additional
research is required to understand the activating factors and balance between these two oppos-
ing effects. Thus, further translational study is envisioned defining the relevance of IL-6 and
VEGF siRNA to other tumor types (including those with variable growth rates) and organs
commonly ablated in clinical practice which may be more or less expressive of these cytokines.
Indeed, given the host of reactions that have been identified in the periablational rim thus far,
it is also likely that a number of other mediators are up-regulated (potentially downstream as
part of the pathway studied here, or as a parallel pathway), such as other mediators of inflam-
mation, the HGF/c-Met pathway, and downstream intracellular activators (such as PI3/Akt or
STAT3 pathways). Several of these may also be potential therapeutic targets that merit further
study. Along these lines, while we have studied radiofrequency-based thermal ablation (as this
is the most commonly used modality in clinical practice), additional study will be required to
determine the extent of applicability of our findings to other methods of ablation including,
cryoablation, microwave thermal ablation, and irreversible electroporation[12]. Indeed, even
higher post-treatment IL-6 levels have been reported for some therapies, such as cryoablation,
compared to RF ablation [19]. Finally, it is possible that administration of the adjuvant drug,
either through siRNA alone, interaction of lipid carrier components in the periablational rim,
or the act of intraperitoneal administration also contributes to the inflammatory response.
Indeed, we have previously shown that lipid components of the nanoparticle can be active
independent from the drug payload [59]. Similarly, siRNA can induce a reactive inflammatory
response [60], which likely explains the marginally higher distant tumor growth rate in the
scrambled siRNA treatment arm (where there are no suppressive effects of the anti-IL6 siRNA)
compared to even RF ablation alone. However, ultimately, the use of adjuvant anti-IL6 siRNA
with RF ablation effectively suppresses any additional increases in inflammation associated
with its administration.
In conclusion, we demonstrate that thermal ablation of normal organ parenchyma (such as
is required in clinical practice) can result in Interleukin-6-mediated locoregional and systemic
effects (including distant tumor growth). We further show that the novel paradigm of
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combining adjuvant nanoparticle anti-IL6 siRNA can be successfully used to suppress poten-
tially pro-oncogenic effects of thermal ablation.
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